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CHAPTER 5
NOREPINEPHRINE-INDUCED BLOOD PRESSURE RISE
AND RENAL VASOCONSTRICTION IS NOT ATTENUATED
BY ENALAPRIL IN MICROALBUMINURIC IDDM 
K. Hoogenberg , G. Navis and R.P.F. Dullaart1 2 1
In non-diabetic subjects an attenuated systemic norepinephrine (NE) responsiveness may
contribute to the mechanisms of action of angiotensin-converting enzyme (ACE) inhibitor treatment.
We determined whether ACE-inhibitor treatment influences systemic and renal haemodynamic
responsiveness to exogenous NE, as well as urinary albumin excretion during NE, in micro-albuminur-
ic IDDM patients, representing a patient category that benefits by strict blood pressure control. In 7
microalbuminuric IDDM patients, systemic and renal responsiveness to NE, infused at individually
determined threshold (Îmean arterial pressure (MAP)=0mmHg), 20% pressor (ÎMAP =4mmHg) and
pressor (ÎMAP=20mmHg) doses, were compared before and after 8 weeks treatment with enalapril,
10 mg daily. Blood glucose was clamped at 5 mmol/l and insulin was infused at 30 mU/kg per h.
Enalapril decreased MAP (p<0.05) and microalbuminuria (p<0.05), whereas effective renal plasma
flow (ERPF) increased (p<0.01) and glomerular filtration rate (GFR) remained unaltered. Filtration
fraction tended to decline (p=0.09). The ACE inhibitor-induced fall in MAP disappeared at NE pressor
dose, and the overall mean increase in MAP in response to NE was even higher with than without
enalapril (p<0.05). After enalapril, ERPF remained higher at all NE doses (p<0.05), but the magnitude
of the NE-induced fall in ERPF was not altered by ACE inhibition treatment. Overnight urinary
albumin excretion fell by ACE-inhibition (p<0.05), but this effect was not seen during NE infusion.
The angiotensin II/active renin ratio and serum aldosterone levels remained lower with enalapril at all
NE doses (p<0.05). In conclusion, enalapril does not attenuate systemic and renal vascular
responsiveness to exogenous NE in microalbuminuric IDDM despite adequate inhibition of the renin-
angiotensin-aldosterone system. These findings suggest that the effect of NE on vasoconstriction is not
effectively counteracted by ACE inhibition treatment alone.
Introduction 
Blockade of the renin-angiotensin-aldosterone system (RAAS) by angiotensin-con-
verting enzyme (ACE) inhibitors lowers blood pressure, (micro)albuminuria and slows
progression of diabetic and non-diabetic renal insufficiency, although such treatment is
unable to completely prevent this serious complication [1-3]. The mechanism of action of
these agents is still incompletely understood. Both angiotensin II-dependent and
independent mechanisms are thought to be involved. The sympathetic nervous system
(SNS) and RAAS are closely related [4] and ACE inhibition may influence systemic
norepinephrine (NE) reactivity. Experimental studies indeed have shown that systemic
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vascular NE responsiveness is attenuated by ACE inhibitors [5,6]. A decrease in systemic
NE responsiveness after ACE inhibition treatment has been demonstrated in hypertensive
subjects [7-9]. Moreover, in healthy subjects the renal vasoconstrictive response has been
found to be reduced after ACE inhibition [10]. This would suggests that attenuation of
renal NE responsiveness may be involved in the renoprotective effect of ACE inhibitors
in non-diabetic subjects.
In insulin-dependent and non-insulin-dependent diabetes mellitus (IDDM and
NIDDM), the systemic vasopressor response to exogenous NE has been repeatedly found
to be enhanced [11-13]. The effect of ACE inhibition on systemic and renal NE respon-
siveness is less well characterised in diabetes mellitus. In patients with NIDDM and in a
heterogeneous group of NIDDM and IDDM patients, treatment with enalapril or captopril
did not normalise the exaggerated systemic NE responsiveness [14,15], but this has not
been studied in IDDM complicated by microalbuminuria. It is of particular relevance to
evaluate the NE responsiveness after ACE-inhibition treatment in microalbuminuric
IDDM patients, because control of factors that contribute to a blood pressure rise in such
patients appears to be indicated to prevent progression to overt nephropathy. The purpose
of our study was, therefore, to evaluate the effect of enalapril treatment on systemic and
renal haemodynamic responsiveness to exogenous NE in IDDM patients with
microalbuminuria.
Subjects and methods 
Subjects 
The study was approved by the local medical ethics committee and all participants
gave written informed consent. The patients were considered insulin-dependent, and
glucagon stimulated C-peptide levels were less than 0.2 nmol/l. Seven patients (6 men, 1
women) participated. They had a mean age of 48±9 (mean±SD) years and a diabetes
duration of 29±5 years. None had severe obesity (body mass index ranging from 23.5 to
27.9 kg/m ). All of the patients had persistent microalbuminuria (defined as an urinary2
albumin excretion rate (Ualb.V) between 20 to 200 µg/min in at least two out of three
overnight urine collections for a 1-year period). All patients were treated with enalapril for
elevated blood pressure related to the presence of incipient nephropathy (systolic/ diastolic
blood pressure >140/90 mmHg), but none had essential hypertension before development
of microalbuminuria. ACE inhibition treatment was stopped for 6 weeks before the start
of the study. Without enalapril, 6 patients had a systolic blood pressure > 140 mmHg and
1 patient had a diastolic blood pressure >90 mmHg. None of the patients had untreated
proliferative retinopathy, symptomatic coronary heart disease, peripheral vascular disease,
or clinical autonomic neuropathy as evaluated by standard tests (beat-to-beat variation
during deep breathing, Valsalva manoeuvre and systolic blood pressure response to
standing). All participants were instructed by dietician to adhere to a diet containing 100
mmol sodium and 1 gram protein/kilogram body weight per day throughout the studies.
Three timed overnight urine collections were obtained directly prior to the studies. 
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Table 1.Baseline characteristics before and after 8 weeks treatment with enalapril.
before ACEi with ACEi
HbA1c (%) 8.4 ±0.2 8.5 ± 0.2
Body weight (kg) 83.2 ± 2.7 83.3 ±2.7
Urinary urea excretion (mmol/day) 279 ±26 282 ± 16
Sodium excretion (mmol/day) 110 ±8 123 ± 10
Mean of 3-timed overnight urinary 71.4 (33.5 - 152.2) 50.9 (36.8 - 97.2)a
albumin excretion rates (µg/min)
Data in mean±SEM, except for urinary albumin excretion rate which is geometric mean (95%
confidence interval). ACEi: angiotensin converting enzyme inhibition.  denotes p<0.05 a
Study design
NE-infusions were performed on three separate study days. On the first day,
systemic MAP-NE dose response curves were made. The individual NE threshold (Îmean
arterial pressure (MAP)=0mmHg), 20% pressor (ÎMAP=4mmHg) and pressor doses
(ÎMAP=20mmHg) were calculated from MAP-NE dose response curves. On a separate
day, the stepwise NE infusions were given with renal function measurements during 10
consecutive 45 min clearance periods. Two baseline periods were followed by 6 periods
of NE (2 periods for threshold, 20% pressor and pressor doses, respectively), after which
2 determinations were obtained after cessation of the infusion (recovery period). Blood
pressure was recorded every 5 min (Dinamap). These systemic and renal haemodynamic
studies were repeated after 8 weeks of treatment with the ACE inhibitor enalapril (10
mg/day), given at 0800 h. The same NE doses were administered during this second
evaluation. The patients also participated in another study that aimed to compare the renal
haemodynamic and microproteinuric NE responses in micro- and normoalbuminuric
IDDM patients and control subjects, and the pre-enalapril data were also used for that
study [13]. One initially studied patient declined to participate in the second evaluation. 
The experiments were carried out in a temperature-controlled room kept at 22 C.o
The subjects were studied after an overnight fast and remained so during the experiments.
Smoking was prohibited and no liquid other than water was allowed to drink. The subjects
remained in supine position and were only allowed to stand on voiding. Two hours before
the start of the renal haemodynamic measurements, each subject drank 600 ml water to
promote diuresis. Thereafter, urinary volume losses were suppleted by water drinking. An
euglycaemic insulin clamp was used to minimise effects of differences in actual glycaemia
on renal haemodynamics [16] and to avoid that changes in insulin levels during the experi-
ments would potentially influence NE sensitivity. Insulin was infused (Velosulin H.M.,
Novo-Nordisk, Bagsvaerd, Denmark) at a rate of 30 mU/kg per h. Blood glucose was kept
at 5 mmol/l by varying the infusion rate of a 20% glucose solution. Potassium chloride (10
mmol per 100 g of glucose) was added to the glucose vials.
GFR and ERPF were measured simultaneously using primed infusions of I-125
iothalamate and I-hippurate, respectively [16]. The clearances were calculated using the131
formula U.V/P and I.V/P, respectively. U.V represents the urinary excretion rate of the
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tracer, I.V represents the infusion rate of the tracer, and P represents the tracer value of
plasma samples taken at the end of each clearance period. Errors in the estimation of GFR
due to incomplete bladder emptying and dead space were corrected by multiplying the
clearance of I-iothalamate with the formula: clearance of I-hippurate (I.V/P) /125 131
clearance of I-hippurate (U.V/P). The coefficients of variation for GFR and ERPF are131
2.2% and 5.0%, respectively [16]. The GFR and ERPF were corrected to 1.73m  of body-2
surface area. Filtration fraction (FF) was calculated as the quotient of I-iothalamate and125
I-hippurate clearances. 131
Analytical methods
Blood samples were taken from an intravenous catheter at the end of each clearance
period with the subjects in supine position. Blood was immediately centrifuged at 4 C ando
samples were stored at -20 C before assay. Aliquots of urine for measurement of urinaryo
proteins were stored at -20 C and analysed within 2 weeks. Plasma insulin was determinedo
by RIA. Plasma NE was analysed by HPLC [17]. Active plasma renin was determined
with a commercially available double-antibody RIA (Nichols Institute Diagnostics, San
Juan Capistrano, CA, USA) with a cross-reactivity with prorenin of 0.2%. Serum ACE
activity was measured with an HPLC technique. Angiotensin II was determined by RIA
(Dept. of Pharmacology, State University Maastricht, The Netherlands). Cross-reactivity
of the angiotensin II antibody with angiotensin I is <0.1%. Serum aldosterone was
determined by RIA. Blood glucose was measured using a Yellow Springs glucose
Analyser (Model 23A, Yellow Springs Inc, Yellow Springs, Ohio, USA). Urinary albumin
was measured with ELISA using rabbit anti-human albumin antibody (DAKO). The
detection limit is 1 µg/l. Sodium, potassium, creatinine and serum albumin in serum and
urine were measured on SMA(C) autoanalysers (Technicon Instruments Inc. Tarrytown,
N.Y., USA). 
Statistical analysis
Results are expressed as mean±SEM for parametrically distributed data and as
geometric mean (95% confidence intervals) for non-parametrically distributed data unless
stated otherwise. The 2 clearance periods obtained at baseline, threshold, 20% pressor,
pressor and recovery were averaged for analysis. Where appropriate, repeated measure-
ments ANOVA for parametrically or non-parametrically distributed data was used to
analyse the effects of the NE-infusions before and after ACE inhibition. Paired t-tests or
Wilcoxon tests were then used to establish differences between corresponding observation
periods. Differences in NE effects on MAP and ERPF before and after ACE inhibition
were evaluated by comparing the overall mean changes of each individual. p-Values less
than 0.05 were considered to be significant. 
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Results 
Metabolic control, body weight, urinary urea and sodium excretion were similar
before and after treatment with enalapril (Table 1). Enalapril lowered baseline MAP by
5%, but did not change pulse rate (Table 2). GFR was unaltered, whereas ERPF increased
by 9% (Table 2). FF tended to fall (p=0.09). Overnight microalbuminuria fell by 28%
(Table 1). Enalapril increased plasma active renin and decreased serum ACE activity and
serum aldosterone levels (Table 3). Baseline plasma AII did not significantly change, but
the AII/active renin ratio profoundly decreased, indicating adequate RAAS inhibition. 
Plasma NE concentrations during NE infusions were similar before and after ACE
inhibition (Table 2). Before enalapril, NE increased MAP at 20%pressor and pressor doses
to target levels (Table 2). With enalapril, NE infusion also increased MAP. At NE pressor
dose there was no difference in MAP compared to before enalapril. The overall mean
increment in MAP was greater during than before enalapril (p<0.05, Figure 1A). At
recovery, MAP was again lower with than without enalapril. ACE inhibition treatment did
not influence the fall in pulse rate at NE-pressor dose and its rise at recovery (Table 2). 
GFR remained essentially unaltered during NE infusions before and after enalapril,
but declined at recovery (Table 2). ERPF progressively decreased at 20% pressor and at
pressor dose both before and during enalapril, and corresponding rises in FF were seen.
During all observation periods, ERPF remained significantly higher with than before
enalapril, and the magnitude of the NE-induced decrease in ERPF was not influenced by
enalapril treatment (Figure1B). The overall urinary albumin excretion rate during NE
infusion was 51.5 (24.3-109.1) µg/min before and 57.6 (26.3-126.3) µg/min after enalapril
(p>0.20).
Before enalapril, plasma active renin, angiotensin II and serum aldosterone levels in-
creased at NE pressor dose, whereas the angiotensin II/active renin ratio remained una-
ltered (Table 3). With enalapril, plasma active renin and serum aldosterone levels rose at
NE-pressor dose, but plasma angiotensin II did not significantly increase. At NE- pressor
dose a slight fall was seen in the angiotensin II/active renin ratio. The overall mean levels
of plasma active renin, serum ACE activity, angiotensin II, the angiotensin II/active renin
ratio and serum aldosterone were lower after enalapril. 
Mean blood glucose and plasma insulin concentrations were 5.2±0.1 and 5.1±0.1
mmol/l and 230±22 and 251±19 pmol/l, before and after enalapril,  respectively (NS). 
Discussion 
As expected, enalapril lowered blood pressure and overnight urinary albumin
excretion, and induced renal vasodilatation in microalbuminuric IDDM patients. The
systemic haemodynamic and the renal responsiveness to exogenous NE, as well as urinary
albumin excretion during NE, were however not altered by ACE inhibition treatment.
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Table 3. Parameters of the renin-angiotensin II-aldosterone system during stepwise
norepinephrine infusions without and with enalapril
Plasma active Angiotensin- Angiotensin II Angiotensin II/ Serum
Renin (mU/l)  convering- (pmol/l) plasma active   aldosteronea a
enzyme (U/l)   renin ratio     (nmol/l)a a
without enalapril
Baseline   61 (33-111) 29 ± 3   15 ± 2 0.26 ± 0.05  360 ± 40
Threshold  55 (32-94) 28 ± 3   14 ± 1 0.28 ± 0.05  330 ± 40
20% Pressor  64 (49-187) 28 ± 4   16 ± 1 0.28 ± 0.06  420 ± 40
Pressor  95 (49-187) 28 ± 4   25 ± 5 0.25 ± 0.05  710 ± 130e e e
Recovery  91 (51-160) 25 ± 3   21 ± 4 0.24 ± 0.03  460 ± 50d
with enalapril
Baseline 121 (41-359)  6 ± 2   14 ± 4 0.10 ± 0.02    90 ± 20b b b
Threshold 127 (49-335)  6 ± 2   11 ± 2 0.09 ± 0.02  100 ± 30b c b
20% Pressor 137 (54-485)  7 ± 2   12 ± 2 0.09 ± 0.02  110 ± 20b b b
Pressor 201 (85-485)  8 ± 2   18 ± 4 0.08 ± 0.01  220 ± 30e b b,d b,e
Recovery 198 (98-402)  9 ± 2   15 ± 2 0.07 ± 0.01  170 ± 40c,d b c,e b
Data in mean±SEM and geometric mean (95% confidence intervals).  p<0.01 overall mean valuesa
without vs with enalapril,  p<0.05 and  p<0.01 from corresponding infusion period beforeb c
enalapril,  p<0.05 and  p<0.01 from baseline valuesd e
Table 2. Systemic and renal hemodynamic parameters during stepwise norepinephrine
infusions without and with enalapril.
Plasma   Mean arterial Pulse   Glomerular   Effective renal Filtration
  norepinephrine pressure  rate   filtration rate  plasma flow   fraction
(nmol/l)    (mmHg) (beats/min) (ml/min/1.73m ) (ml/min/1.73m )  (%) 2 2
without enalapril
Baseline   2.9 (2.1-4.2)    98± 2  70 ± 5 107 ± 9   460 ± 40 23 ± 1
Threshold  5.1 (4.0-6.6)  100 ±1 66 ± 4 111 ±10   427 ± 40 26 ± 1
20% Pressor  6.6 (5.1-8.6)  102 ± 2 66 ± 4 110 ± 9   400 ± 34 28 ± 1c d d
Pressor 17.7(10.3-30.2)  118 ±1 63 ± 4  109 ± 9  318 ± 22 34 ± 2d d d d
Recovery  3.6 (2.4-5.4)    95 ± 3 76 ± 5  97 ± 10 398 ± 32 24 ± 1 d d d
with enalapril
Baseline  2.9 (2.0-4.0)    92 ± 3 67 ± 4 111 ± 11 500 ± 44 22 ± 1 a b
Threshold  5.7 (4.8-6.9)    96 ± 2 65 ± 4 117 ± 12 463 ± 38 25 ± 1a a d
20% Pressor  6.3 (4.8-8.2)    98 ± 2 65 ± 4 116 ± 11 431 ± 35 27 ± 1a,c a,c d
Pressor 18.7 (11.1-31.5) 116 ± 2 62 ± 4 115 ± 10 352 ± 27 33 ± 1d d a,d d
Recovery  4.2 (2.9-6.0)    87 ± 3 74 ± 4 102 ± 9 460 ± 34 22 ± 1 b d c b
Data in mean±SEM and geometric mean (95% confidence intervals).  p<0.05 and  p<0.01 froma b
corresponding infusion period without enalapril,  denotes p<0.05 and  denotes p<0.01 fromc d
baseline 
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Figure 1(A,B). Plot comparing individual changes in mean arterial pressure (MAP, A) and effective
renal plasma flow (ERPF, B) in response to stepwise norepinephrine infusions before and after ACE
inhibition. The lines indicate identical changes. Overall mean change in MAP was greater with than
without enalapril (n=7, p<0.05 by paired Wilcoxon test). No difference in overall ERPF response was
observed.
Chapter 588
Apart from general factors like basal vasomotor tone and vascular reactivity, sodium
and volume homeostasis, as well as baroreceptor feedback control are determi
nants of the systemic reactivity to exogenous NE, and may thus contribute to an enhanced
systemic NE responsiveness in diabetes mellitus [8,11,13,18]. Such an exaggerated
responsiveness has been found to be associated with an increased exchangeable sodium
and a higher extracellular volume, and this hyperreactivity decreases after diuretic
treatment  [11]. In addition, microalbuminuric IDDM patients have an attenuated pulse
rate decline during NE infusion [13], which suggests that an altered baroreceptor
feedback control may also contribute to the systemic NE hyperresponsiveness in IDDM
[18]. 
The observation that enalapril treatment failed to diminish systemic vascular NE
reactivity in microalbuminuric IDDM is in keeping with previous findings in diabetic
patients [11,12]. By contrast, in essential hypertension, the systemic responsiveness to NE
appears to be attenuated after ACE inhibition treatment [7-9]. Several factors could be
involved in the lack of attenuation of the systemic NE responsiveness after ACE inhibition
in diabetes mellitus. First, ACE inhibition therapy is unlikely to have influenced sodium
and volume status in the present study since body weight remained unchanged. Indeed,
captopril does not significantly decrease exchangeable sodium in diabetes mellitus [14].
In this respect, it is noteworthy that ACE inhibition treatment induces a negative sodium
balance in essential hypertension [19]. Second, a similar heart rate decline during NE
before and after enalapril was observed, suggesting no important alterations in
baroreceptor sensitivity, in agreement with findings in hypertensive diabetic patients [14].
Third, although enalapril induced adequate RAAS suppression, it cannot be excluded that
a more complete inhibition of angiotensin II formation is required to blunt systemic NE
reactivity. Finally, we consider a type II error very unlikely to explain the lack of attenua-
tion of enalapril on systemic NE reactivity, since the mean increment in MAP in response
to NE was even higher after ACE inhibition. 
This study is the first to document the effect of ACE-inhibition treatment on NE-
induced renal vasoconstriction in microalbuminuric IDDM patients. In IDDM, ACE
inhibitors increase renal plasma flow without having much effect on glomerular filtration
rate. As a consequence, filtration fracttends to decline [20]. These changes are ascribed
to a predominantly postglomerular dilatation which is in part due to decreased angiotensin
II formation. In our study, the renal vasodilatory effects of enalapril remained present
during NE infusion, a finding thus far only documented in healthy volunteers [10].
Enalapril prevented the rise in angiotensin II levels during NE pressor infusion. It may
thus be inferred that this partial RAAS blockade accounted for the ongoing renal
vasodilatation of the ACE inhibitor during NE infusion as compared to pretreatment.
Although difficult to demonstrate in humans, animal studies have unequivocally docu-
mented bidirectional interactions between the RAAS and the SNS in a way such that each
system is able to potentiate the other [4]. ACE inhibition treatment could, therefore,
induce a decrease in SNS activation. In the isolated kidney, ACE inhibitors indeed have
been demonstrated to diminish renal vascular NE responsiveness [5,6], and neuronally-
induced renal vasoconstriction [21], suggesting interference in the RAAS-SNS interaction.
The present in vivo study does, however, not support the assumption of an intrarenal
sympathicolytic effect of enalapril in microalbuminuric IDDM patients, since the
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exogenous NE-induced fall in ERPF was not altered by ACE inhibition treatment. 
Our findings may have clinical implications for the future design of renoprotective
strategies in IDDM patients. Currently, ACE inhibition treatment is considered to be the
main tool to retard the decline in renal function loss in IDDM, both by lowering systemic
blood pressure and by decreasing intraglomerular pressure [1-3]. Despite this proven
renoprotective potential, many patients still progress to end stage renal failure. Albeit in
a small number of patients, the present study is consistent with the possibility that
microalbuminuric IDDM patients are not sufficiently protected by ACE inhibition
treatment against rises in systemic blood pressure due to bouts of SNS activation during
daily life activities. Although the effects of exogenous NE cannot be directly extrapolated
to physiological SNS stimulation, it is noteworthy that increases in urinary albumin excre-
tion are well related to rises in blood pressure and plasma NE levels during exercise,
which represents a strong endogenous SNS stimulus [17].
In conclusion, we found that enalapril does not attenuate systemic and renal vascular
responsiveness to exogenous NE in microalbuminuric IDDM patients. These findings
suggest that a potentially adverse effect of NE on systemic and renal vascular tone is not
effectively counteracted by ACE inhibition treatment alone.
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